Tandem Diabetes Care Net Common Equity Issued/Repurchased 2012-2025 | TNDM
Tandem Diabetes Care net common equity issued/repurchased from 2012 to 2025. Net common equity issued/repurchased can be defined as the net dollar amount of transactions to issue and repurchase common stock.
| Tandem Diabetes Care Annual Net Common Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $-37 |
| 2023 | $4 |
| 2022 | $17 |
| 2021 | $52 |
| 2020 | $70 |
| 2019 | $24 |
| 2018 | $32 |
| 2017 | $1 |
| 2016 | $2 |
| 2015 | $3 |
| 2014 | $4 |
| 2013 | $3 |
| 2012 | $0 |
| 2011 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $1.431B | $0.940B |
| Tandem Diabetes Care, Inc. designs, develops and markets products for people with insulin-dependent diabetes. The company's flagship product, the t:slim X2 Insulin Delivery System, or t:slim X2, is based on its proprietary technology platform. Per the company, t:slim X2 is the smallest durable insulin pump available and is also the only available pump capable of remote feature updates.Tandem Diabetes also offers t:flex insulin delivery system which includes t:flex pump, its 480-unit disposable insulin cartridge, an infusion set, t:lock cartridge and infusion set products, various pump accessories along with t:slim X2 with G5 integration. | |||